Trials / Recruiting
RecruitingNCT03680677
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bone Marrow or Peripheral Blood Graft (BMT) | Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol. |
| OTHER | Cancer-directed Therapy or Best Supportive Care | Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care. |
| DIAGNOSTIC_TEST | Frailty Assessment | Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors. |
Timeline
- Start date
- 2018-09-21
- Primary completion
- 2026-06-22
- Completion
- 2026-11-01
- First posted
- 2018-09-21
- Last updated
- 2025-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03680677. Inclusion in this directory is not an endorsement.